Market Overview

UPDATE: Morgan Stanley Reiterates on Pfizer as Vaccine Pipeline is Under-Appreciated

Share:
Related PFE
These Companies Probably Won't Be Acquiring Ariad Pharmaceuticals
Morgan Stanley's Major Pharma Q1 Preview
Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog (Zacks)

In a report published Friday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Pfizer (NYSE: PFE), and raised the price target from $34.00 to $36.00.

In the report, Morgan Stanley noted, “We believe Pfizer can outperform the pharma group given its potential for positive pipeline news and strategic action. Mgmt is committed to share repurchase and dividend increases. Financial and strategic action should continue to drive shareholder value.”

Pfizer closed on Thursday at $31.12.

Latest Ratings for PFE

DateFirmActionFromTo
Mar 2015JefferiesMaintainsBuy
Mar 2015Deutsche BankMaintainsBuy
Feb 2015JefferiesMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...